59
Participants
Start Date
October 8, 2021
Primary Completion Date
July 21, 2023
Study Completion Date
November 26, 2024
Pembrolizumab
Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
SAR444245 (Thor-707)
Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
Cetuximab
Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
Investigational Site Number : 1580003, Tainan City
Investigational Site Number : 0320001, Buenos Aires
Investigational Site Number : 5280002, Amsterdam
Investigational Site Number : 2760004, Berlin
Thomas Jefferson University Hospital Site Number : 8400003, Philadelphia
Investigational Site Number : 3800003, Brescia
Investigational Site Number : 7240005, Madrid
Investigational Site Number : 7240003, Madrid
Investigational Site Number : 2500003, Bordeaux
University of Michigan- Site Number : 8400008, Ann Arbor
Investigational Site Number : 2500002, Strasbourg
Investigational Site Number : 2500008, Lyon
Investigational Site Number : 2500006, Paris
University of Colorado- Site Number : 8400004, Aurora
City of Hope- Site Number : 8400007, Duarte
Investigational Site Number : 2500001, Villejuif
Seattle Cancer Care Alliance Site Number : 8400006, Seattle
Investigational Site Number : 1520004, Viña del Mar
Investigational Site Number : 1520002, Temuco
Investigational Site Number : 1520003, Santiago
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 1240001, Montreal
Investigational Site Number : 5280001, Nijmegen
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 7240001, Barcelona
Investigational Site Number : 7240004, Barcelona
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Sanofi
INDUSTRY